Clinical Trials Logo

Idiopathic Gastroparesis clinical trials

View clinical trials related to Idiopathic Gastroparesis.

Filter by:

NCT ID: NCT01696747 Completed - Gastroparesis Clinical Trials

Gastroparesis Registry 2

GpR2
Start date: July 2012
Phase:
Study type: Observational

To expand a registry of patients for the study of the epidemiology, etiology, and degree of morbidity associated with gastroparesis.

NCT ID: NCT01625923 Terminated - Clinical trials for Idiopathic Gastroparesis

A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis

Start date: January 2013
Phase: N/A
Study type: Interventional

Gastroparesis is a disorder characterized by impaired gastric emptying in the absence of obstruction in the proximal GI tract. It is a common condition affecting up to 5 million persons in the United States alone. Despite this, metoclopramide is currently the only FDA approved medication for the treatment of gastroparesis. However, the evidence supporting metoclopramide in gastroparesis is fairly weak and was recently issued a black box warning because of potential irreversible side effects. There is clearly an urgent need for newer therapeutic options with better efficacy and tolerability. Olanzapine is a second generation anti-psychotic that is currently FDA approved for the treatment of schizophrenia and bipolar disorder. Because of actions at several receptors throughout the body, including dopamine and serotonin receptors, Olanzapine may provide anti-nausea and pro-motility effects in the stomach. Long-term use of olanzapine may also increase plasma levels of ghrelin. Ghrelin is a hormone produced by the gut that stimulates appetite and has also been shown to have beneficial effects on gastroparesis. The investigators hypothesize that olanzapine will be effective and safe in controlling symptoms as well as stimulate appetite and weight gain in gastroparesis. The investigators also hypothesize that olanzapine will stimulate gastric motility. Finally, the investigators hypothesize that olanzapine will modulate the secretion of ghrelin in gastroparesis. This pilot study may provide further information on the efficacy and safety of olanzapine in gastroparesis which could be utilized in a larger randomized, prospective study in the future.

NCT ID: NCT00765895 Completed - Clinical trials for Idiopathic Gastroparesis

Nortriptyline for Idiopathic Gastroparesis

NORIG
Start date: January 2009
Phase: Phase 3
Study type: Interventional

The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether treatment with nortriptyline will improve gastroparesis symptoms compared with placebo.